Quick Answer: Compounding pharmacy requirements are a complex set of federal and state rules. The FDA’s 503A and 503B classifications define these rules. Quality standards come from the United States Pharmacopeia (USP).
Context: As of 2026, following the rules is more important than ever. The FDA is enforcing rules more strictly after the 2024 USP standards update. More people want custom medications.
Key Takeaway: This guide combines the three main parts of compounding rules. These are FDA classification (503A/503B), USP quality standards (<795>, <797>, <800>), and State Board of Pharmacy licensing. Together, they form one clear framework you can use.
Key Takeaways
- Federal Law Sets the Rules: The U.S. Food and Drug Administration (FDA) groups compounding facilities into two types. These are 503A (traditional, patient-specific pharmacies) and 503B (larger-scale outsourcing facilities). This difference is the most important factor. It determines your regulatory path.
- Quality Standards Are Required: The United States Pharmacopeia (USP) sets national quality standards. Chapters (non-sterile), (sterile), and (hazardous drugs) are the basic rules for safe compounding practices.
- State Law Controls Licensing and Enforcement: The FDA and USP set the framework. But individual State Boards of Pharmacy issue licenses. They also conduct inspections and enforce rules for most compounding pharmacies (503A facilities).
- Accreditation Shows Excellence: Voluntary accreditation from groups like the Pharmacy Compounding Accreditation Board (PCAB) is becoming standard. Some states and payers now require it as proof of high-quality work.
The Two Main Parts of Federal Rules: 503A vs. 503B
Compounding regulation in the United States is built on the difference between 503A and 503B facilities. The Federal Food, Drug, and Cosmetic (FD&C) Act defines this classification. This classification determines everything. It affects prescription requirements and which regulatory body you must answer to. Understanding this difference is the first step toward following the rules.
What is a 503A Compounding Pharmacy?
A 503A facility is what most people think of as a traditional compounding pharmacy. Its main job is to prepare custom medications for a specific patient. These medications are based on a valid prescription. State Boards of Pharmacy regulate these pharmacies. These boards typically include USP standards in their state laws and rules. They are exempt from certain federal requirements. These include new drug approval and federal labeling rules. This exemption applies as long as they operate within section 503A conditions.
What is a 503B Outsourcing Facility?
A 503B outsourcing facility is a newer category. The Drug Quality and Security Act (DQSA) of 2013 created it. These facilities can compound large batches of sterile drugs. They can do this with or without patient-specific prescriptions. They can then sell these drugs to healthcare providers (like hospitals and clinics) for office use. To operate as a 503B, a facility must register with the FDA voluntarily. They must also follow much stricter standards called Current Good Manufacturing Practices (CGMP). This higher regulatory bar gives them more flexibility in production and distribution. Data from one analysis shows the clear difference in regulatory expectations between these two models.
503A vs. 503B: Key Differences
This table provides a clear comparison of the two regulatory models.
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Primary Regulation | State Boards of Pharmacy | FDA |
| Prescription Requirement | Patient-specific prescription required | Not required; can sell to providers for office stock |
| Quality Standard | USP <795>, <797>, <800> | Current Good Manufacturing Practices (CGMP) |
| Interstate Shipping | Limited, based on state laws (e.g., MOU) | Permitted nationwide |
| FDA Registration | Not required | Voluntary, but required to operate as 503B |
| Adverse Event Reporting | Varies by state | Mandatory to FDA |
USP General Chapters: The Foundation of Quality and Safety
Federal law defines the type of pharmacy. The United States Pharmacopeia (USP) defines the quality of the work done in it. USP General Chapters are science-based standards. They ensure compounded preparations are safe and effective. Following these chapters is not optional. It is a core requirement. State Boards of Pharmacy enforce it. Accreditation bodies expect it.
USP <795>: Pharmaceutical Compounding – Nonsterile Preparations
USP <795> provides standards for compounding non-sterile preparations. These include common forms like creams, ointments, capsules, and oral liquids. The chapter outlines essential requirements for every step of the process. This includes personnel training and facility cleanliness. It also covers ingredient sourcing and verification. It establishes beyond-use dates (BUDs) to ensure stability. It requires proper documentation.
USP <797>: Pharmaceutical Compounding – Sterile Preparations
USP <797> is the set of standards designed to prevent patient harm from germs in sterile preparations. This applies to high-risk medications. These include injections, IV solutions, and eye drops. Key requirements are much stricter than for non-sterile compounding. They focus on creating and maintaining a germ-free environment. This includes specifications for cleanroom environments (ISO-classified air quality). It requires proper aseptic technique and strict environmental monitoring. It also requires detailed protocols for personnel garbing and gloving. Recent revisions have made these standards even stricter. This directly impacts pharmacy design and how often testing is required.
USP <800>: Hazardous Drugs – Handling in Healthcare Settings
USP <800> focuses on protecting healthcare personnel, patients, and the environment from exposure to hazardous drugs (HDs). This chapter applies to all healthcare settings where HDs are handled. This includes compounding pharmacies. Unlike <795> and <797>, which prioritize product quality, <800> is mainly about personnel and environmental safety. It requires specific containment strategies. These include using biological safety cabinets or compounding aseptic containment isolators. It requires personal protective equipment (PPE). It establishes clear protocols for every stage from receipt and storage to compounding and disposal.
Path to Following Rules: A Timeline for New Compounding Pharmacies
Setting up a compliant compounding pharmacy is a complex, multi-stage process. It requires careful planning and execution. For those looking to Open a Pharmacy, understanding this timeline is crucial for a successful launch.
-
Phase 1 (Months 1-3): Strategic Planning & Legal Structure
- Decision Point: Decide between the 503A and 503B business model. This choice will dictate your entire regulatory and operational strategy.
- Foundation: Establish your business entity (like LLC or S-Corp). Develop a business plan and secure initial funding.
- Guidance: Work with regulatory consultants and legal counsel who specialize in pharmacy law. This early investment can prevent costly mistakes.
-
Phase 2 (Months 4-9): Facility Design & State Licensing
- Build-Out: Design your facility to meet the specific requirements of USP <797> (for sterile) and <800> (for hazardous drugs). This includes cleanrooms, ventilation, and material flow.
- Application: Begin the detailed application process with your State Board of Pharmacy. This often requires submitting facility blueprints and policies and procedures for review.
- Leadership: Appoint a qualified Pharmacist-in-Charge (PIC). This person will be legally responsible for the pharmacy’s compliance.
-
Phase 3 (Months 10-12): Sourcing, Staffing & SOPs
- Supply Chain: Establish relationships with suppliers of Active Pharmaceutical Ingredients (API) from FDA-registered facilities.
- Team Building: Hire and conduct intensive training for all staff. Train them on aseptic technique, USP standards, and your specific Standard Operating Procedures (SOPs).
- Documentation: Develop, write, and validate all SOPs. These should cover every aspect of the compounding process, from receiving ingredients to dispensing the final product.
-
Phase 4 (Launch & Post-Launch): Inspection & Accreditation
- Go-Live: Successfully pass your pre-opening inspection by the State Board of Pharmacy. This gets you your license to operate.
- Excellence (Recommended): Immediately begin the Pharmacy Compounding Accreditation Board (PCAB) accreditation process. This shows a commitment to the highest quality standards.
- Maintenance: Implement a strong continuous quality improvement (CQI) program. This includes ongoing environmental monitoring and staff competency assessments.
Which Type of Compounding Pharmacy Are You? A Decision Framework
Choosing your path can be overwhelming. This simple framework helps clarify the decision based on your intended business activities.
- Start Here: Do you intend to compound medications without a patient-specific prescription (like for hospital or office stock)?
- → If YES: You must register as a 503B Outsourcing Facility. The FDA will regulate your operations directly. You must comply with the strict Current Good Manufacturing Practices (CGMP). This is a capital-intensive path. It requires significant investment in infrastructure and quality systems.
- → If NO: You will operate as a 503A Pharmacy. Your primary business will be filling individual prescriptions. Continue to the next question.
- Next Question: Will you be compounding sterile preparations (like injectables, IVs, eye drops)?
- → If YES: Your facility and processes must fully comply with USP <797> and all relevant state board regulations for sterile compounding. If you handle any hazardous drugs, USP <800> also applies. This adds another layer of containment and safety requirements.
- → If NO: You will mainly follow the standards outlined in USP <795> for non-sterile compounding (like creams and capsules). You must still follow all applicable state board regulations. If you handle any hazardous drugs in non-sterile forms, USP <800> requirements for handling and containment still apply.
- Next Question: Will you be compounding sterile preparations (like injectables, IVs, eye drops)?
State-Level Requirements & Licensing
Federal laws and USP standards create a national framework. But the day-to-day regulation of most compounding pharmacies (503A) falls to the State Boards of Pharmacy. These state-level bodies are the primary authority for licensing, inspection, and disciplinary action.
The Role of the State Board of Pharmacy
Each state has its own pharmacy practice act and associated regulations that govern compounding. According to the National Association of Boards of Pharmacy (NABP), over 87% of state boards now require some form of compliance with USP standards. This effectively makes them law within those jurisdictions. The board is responsible for ensuring that pharmacies operating within their state meet these standards to protect public health.
Common State-Level Requirements
When applying for a license, compounding pharmacies must typically provide:
* Pharmacist-in-Charge (PIC): A designated, licensed pharmacist who is responsible for all pharmacy operations and compliance.
* Licensure: Applications for both resident (in-state) and non-resident (mail-order) pharmacy licenses. These often require more detailed information for compounders than for traditional pharmacies.
* Documentation: Submission of detailed facility blueprints and comprehensive policies and procedures manuals. Also evidence of staff training and competency assessments.
* Inspections: The pharmacy must pass a physical inspection by the board before a license is granted.
Navigating Interstate Commerce
For 503A pharmacies that wish to ship compounded medications across state lines, the regulatory landscape becomes more complex. Many states require non-resident licensure. Furthermore, the FDA has established Memorandums of Understanding (MOUs) that states can sign. These agreements govern the oversight of pharmacies that ship significant quantities of compounded drugs to other states. They create a system for information sharing between states and the FDA.
Frequently Asked Questions (FAQ)
Do compounded medications require a prescription?
Yes. According to industry standards and federal law, all medications prepared in a 503A compounding pharmacy require a valid, patient-specific prescription from a licensed healthcare provider. Facilities operating under 503B regulations are the exception. They can compound in bulk for “office use” without individual prescriptions but are held to stricter manufacturing standards.
Are compounded drugs FDA-approved?
No, and this is a critical distinction. Unlike mass-produced drugs from large manufacturers, compounded medications are not FDA-approved. This means the FDA has not reviewed them for safety, effectiveness, or quality before they reach the patient. Instead, the FDA regulates the practice and facilities where compounding occurs. This ensures that safety and quality standards (like USP chapters and CGMP) are met.
Can a compounding pharmacy copy a commercially available drug?
Generally, no. Federal law prohibits compounding drugs that are “essentially a copy” of a commercially available, FDA-approved drug product. This practice is not allowed to prevent compounders from acting as manufacturers and undermining the drug approval process. Exceptions are permitted in specific circumstances. This is most notably during a documented drug shortage when the commercial product is unavailable.
What is the difference between compounding and manufacturing?
The core difference lies in scale and patient specificity. Compounding is the creation of a drug tailored to the needs of an individual patient based on a prescription from a practitioner. Manufacturing is the mass production of FDA-approved drugs in large quantities for broad distribution without patient-specific prescriptions. 503B outsourcing facilities operate in a hybrid space. They use manufacturing-level quality standards (CGMP) to produce larger batches than a 503A pharmacy. But they don’t go through the full new drug approval process.
Author & Methodology
About the Author
Steven Guo is an industry analyst specializing in the intersection of retail environments and regulatory compliance. With extensive knowledge in commercial material selection, store layout design, and operational workflows, he provides insights into how physical infrastructure impacts safety and efficiency standards in specialized sectors like pharmacy.
Our Research Process
This guide was compiled by combining the latest versions of FDA guidance documents, the official texts of USP General Chapters <795>, <797>, and <800>, and a comprehensive review of regulations from a cross-section of state boards of pharmacy. The information provided is for educational purposes and is not a substitute for professional legal advice. Always consult with a qualified regulatory consultant or legal professional for guidance on your specific compliance needs.
